Lupin receives FDA approval for Sevelamer Carbonate tabs
25 January 2021 | News
Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis
Source credit: Shutterstock
Lupin Limited, a global pharmaceutical company, announced that it has received approval for its Sevelamer Carbonate tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela® tablets, 800 mg, of Genzyme Corporation.
Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Sevelamer Carbonate tablets (RLD: Renvela®) had estimated annual sales of $348 million in thUS (IQVIA MAT September 2020).
